Materials<\/p>\n
View<\/a><\/p>\n Read More<\/a><\/p>\n <\/div>\n The 11th International Conference on Children\u2019s Bone Health took place in Salzburg, Austria, from 22\u201325 June 2024 and was attended by 470 delegates from over 45 countries.<\/p>\n In this congress review, we have highlighted the key We hope you find this summary of the congress useful. <\/strong> View<\/a><\/p>\n <\/div>\n Read More<\/a><\/p>\n <\/div>\n <\/div>\n <\/article>\n \n \n \n \n Materials<\/p>\n View<\/a><\/p>\n Read More<\/a><\/p>\n <\/div>\n The 30th American College of Medical Genetics and We have highlighted the key abstracts from the congress, We hope you find this selection of summaries useful!<\/strong> EUCAN-VOX-00431 May 24<\/p>\n View<\/a><\/p>\n <\/div>\n Read More<\/a><\/p>\n <\/div>\n <\/div>\n <\/article>\n \n \n \n \n Materials<\/p>\n View<\/a><\/p>\n Read More<\/a><\/p>\n <\/div>\n The 61st annual meeting of the European Society for Paediatric Endocrinology (ESPE) took place in The Hague, Netherlands, from 21\u201323 September 2023. The theme for the meeting was Global Challenges in Paediatric Endocrinology, which included sessions on growth, as well as bone, growth plate, and mineral metabolism.<\/p>\n We have picked out abstracts with a focus on children with achondroplasia. This includes new clinical data, real-world analyses, and a look at the underlying genetics. Also summarised is a sponsored symposium, looking at integrating clinical and real-world evidence to improve strategies.<\/p>\n We hope this selection of summaries is useful to you, and perhaps shines a light on ways in which we can address global challenges in our own small corner of endocrinology.<\/strong><\/p>\n EUCAN-VOX-00074 November 2023<\/p>\n View<\/a><\/p>\n <\/div>\n Read More<\/a><\/p>\n <\/div>\n <\/div>\n <\/article>\n \n \n \n \n Materials<\/p>\n View <\/a><\/p>\n Read More<\/a><\/p>\n <\/div>\n March 2023 saw the Annual Clinical Genetics Meeting take place in Salt Lake City, US, attended by delegates from around the world. Across more than 50 educational sessions, presenters shared news about the latest developments in medical genetics.<\/p>\n Year on year the volume of data around achondroplasia at meetings like this is growing, alongside increasing awareness and understanding of the condition. We have chosen a handful of key abstracts presented in the session on clinical genetics and therapeutics. This includes data from the Phase 2 and 3 clinical trials of vosoritide , as well as real-world observational data that shines a spotlight on quality of life and the surgical burden associated with achondroplasia.<\/p>\n We hope you will enjoy the selection summarised for you here.<\/strong><\/p>\n EU-VOX-00819 March 2023<\/p>\n View <\/a><\/p>\n <\/div>\n Read More<\/a><\/p>\n <\/div>\n <\/div>\n <\/article>\n \n \n \n \n Materials<\/p>\n View<\/a><\/p>\n <\/div>\n The 60th annual meeting of the European Society for Paediatric Endocrinology took place 15\u201317 September in Rome, Italy. Over 3,000 delegates attended for a huge programme on diseases of childhood, including dedicated sessions on bone, growth, and mineral metabolism. We have chosen a selection of abstracts with a focus on achondroplasia and a few other topics of interest in the wider field of skeletal dysplasia. These include new analyses of appropriate patient-reported outcomes to use in children with achondroplasia, and examination of differences in everyday management.<\/p>\n Also summarised is a sponsored symposium giving more detail on some of the early-use, real-world cohorts of patients receiving vosoritide in routine practice across Europe.<\/p>\n We hope you will enjoy the selection of presentations summarised for you here.<\/strong><\/p>\n View<\/a><\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/article>\n \n \n \n \n Materials<\/p>\n View<\/a><\/p>\n <\/div>\n The 10th International Conference on Children\u2019s Bone Health took place in Dublin from 2\u20135 July 2022. The meeting brought together scientists, clinicians, and allied health professionals from a variety of disciplines to gain a better understanding of the growing skeleton in health and disease, with leading experts delivering new insights into both molecular mechanisms and a range of clinical aspects, from bone physiopathology to treatment.<\/p>\n As always, it is encouraging to see groups sharing posters and oral communications on the natural history and treatment of achondroplasia, which hopefully will translate into greater awareness and understanding of the condition.<\/p>\n View<\/a><\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/article>\n \n \n \n \n Materials<\/p>\n View<\/a><\/p>\n Read More<\/a><\/p>\n <\/div>\n Our review of EPOS 2021 includes summaries of many advances in the treatment and management of achondroplasia. Our summaries include new technologies to improve limb lengthening, a complex procedure with a high complication rate and no consensus on its use in achondroplasia, but one that could result in height enhancement in adults with achondroplasia, nonetheless.<\/p>\n EU-VOX-00185 10\/21<\/p>\n Our congress reviews provide an overview of the latest developments in achondroplasia.<\/strong><\/p>\n View<\/a><\/p>\n <\/div>\n Read More<\/a><\/p>\n <\/div>\n <\/div>\n <\/article>\n \n \n \n \n Materials<\/p>\n ICCBH Congress Review 2024\n<\/h2>\n
\nabstracts from ICCBH, focusing on the clinical data
\non vosoritide\u25bc and other therapies in development for
\nachondroplasia; as well as multidisciplinary management;
\nand the importance of following up infants with spinal cord
\ncompression rated AFMS3. There is also a brief summary
\nof the ISCBH ERN BOND workshop.<\/p>\n
\nThe Achondroplasia Team<\/strong><\/p>\n ACMG 2024 12-16 March 2024\n<\/h2>\n
\nGenomics (ACMG) Annual Clinical Genetics Meeting took
\nplace in Toronto, Canada, from 12th\u201316th March 2024.
\nAttended by geneticists from around the world, this year\u2019s
\nmeeting saw achondroplasia on the programme in the
\nform of a debate featuring Dr Janet Legare and Dr Julie
\nHoover-Fong discussing whether all patients should be
\nstarted on vosoritide\u25bc.<\/p>\n
\nfocusing on achondroplasia and new clinical data on
\nvosoritide, real-world analysis of double heterozygosity
\nin skeletal dysplasia, and the importance of genetic
\ncounselling in helping families make informed decisions
\nduring prenatal diagnostic testing.<\/p>\n
\nThe Achondroplasia Team<\/strong><\/p>\nESPE 2023-21-23 September 2023\n<\/h2>\n
ACMG 2023-14-18 March 2023\n<\/h2>\n
ESPE 2022-15-17 September 2022\n<\/h2>\n
ICCBH 2022-02-05 July 2022\n<\/h2>\n
EPOS 2021\n<\/h2>\n